These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 16879929

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 8. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 01; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 9. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 15; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 14. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 15. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA.
    J Urol; 2003 Mar 01; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [Abstract] [Full Text] [Related]

  • 16. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, Kimming B.
    Strahlenther Onkol; 2006 Mar 01; 182(3):135-41. PubMed ID: 16520907
    [Abstract] [Full Text] [Related]

  • 17. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):993-1002. PubMed ID: 15752878
    [Abstract] [Full Text] [Related]

  • 18. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):341-6. PubMed ID: 18597953
    [Abstract] [Full Text] [Related]

  • 19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 20. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.